1. Home
  2. TWO vs ABUS Comparison

TWO vs ABUS Comparison

Compare TWO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Two Harbors Investment Corp

TWO

Two Harbors Investment Corp

HOLD

Current Price

$11.56

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.09

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWO
ABUS
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
929.6M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
TWO
ABUS
Price
$11.56
$4.09
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$12.56
$5.00
AVG Volume (30 Days)
2.2M
2.1M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
12.35%
N/A
EPS Growth
N/A
55.26
EPS
N/A
N/A
Revenue
N/A
$14,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$239.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
128.21
52 Week Low
$8.84
$3.04
52 Week High
$14.17
$5.10

Technical Indicators

Market Signals
Indicator
TWO
ABUS
Relative Strength Index (RSI) 66.98 39.99
Support Level $9.74 $3.41
Resistance Level $14.17 $4.71
Average True Range (ATR) 0.10 0.20
MACD 0.00 -0.04
Stochastic Oscillator 93.70 9.46

Price Performance

Historical Comparison
TWO
ABUS

About TWO Two Harbors Investment Corp

Two Harbors Investment Corp is a real estate investment trust focused on investing in, financing, and managing residential mortgage-backed securities, or RMBS; residential mortgage loans; mortgage servicing rights; and commercial real estate. The majority of the company's investment portfolio is split between agency RMBS purchased from government-sponsored enterprises and nonagency RMBS. Two Harbors derives nearly all of its revenue in the form of interest income collected from its investments. The majority of this income is generated by available-for-sale securities, while residential mortgage loans held for investment in securitization trusts also contribute a sizable amount.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: